Background and aims Nicotine replacement therapy (NRT) may be more effective in aiding smoking cessation if higher
INTRODUCTION
Nicotine replacement treatment (NRT) is a widely used medication for smoking cessation, but its efficacy is modest [1] .
Two approaches were suggested that could enhance treatment efficacy: Increasing nicotine dose, and including a pre-quit period of NRT dosing to weaken the conditioned link between smoking behaviour and central reward.
Existing NRT products provide only modest nicotine levels. There is some evidence that slightly increased NRT doses generate better quit rates than standard doses and that combination NRT achieves better results than single NRT [2] . It is possible that an NRT dose that is based on individual needs would be more effective than standard NRT doses. A cohort study reported on NRT doses titrated to the clients' blood cotinine levels seen during ad lib smoking. With an average patch dose of 33 mg/day (maximum dose 63 mg), six-month point-prevalence abstinence rates were 59% [3] . This is promising, although without a control group difficult to interpret. A randomised trial tested NRT doses adjusted for salivary cotinine obtained from smoking, compared to standard NRT [4] . The highest nicotine patch dose was 162 mg. Prolonged 12-week abstinence rates were higher in the tailored NRT group but not significantly so (30% vs. 26%, ns). However, the first dose titration did not occur until 2 weeks after the TQD. The first week or two seem to be the most important period of the quit attempt [5] and any change in dose after this point could be too late.
Regarding nicotine 'pre-loading', where NRT is used prior to the quit day, a Cochrane review [2] identified eight relevant trials. There was some evidence that patch preloading is effective compared to initiating patches from the quit day (RR 1.34, 95% CI 1.08 to 1.65, 6 trials). There is also some evidence that pre-loading using varenicline and bupropion is effective [6] [7] [8] . These studies are relevant because they are examining the same hypothetical active ingredient, that is, reducing the need to smoke.
The largest study of this concept to date (n = 1792) has been recently completed [9] . Participants were asked to smoke ad-lib during 4-weeks of pre-loading with nicotine patches, and the intervention had a modest but significant effect. As in other studies, pre-loading was well tolerated.
Given the potential of tailoring NRT dose to individual needs, nicotine pre-loading effects could be enhanced if the two approaches are combined. Increasing the NRT dosing while smokers still smoke could make smoking unrewarding or even aversive; and higher doses for smokers who can tolerate them may be more effective in reducing withdrawal discomfort after smoking cessation.
Although the hypothesis has a strong rationale, it raises issues concerning possible side effects and acceptability of the approach to patients. The early concerns about cardiovascular effects of NRT were largely dispelled. The UK Committee on the Safety of Medicines reviewed the cardiac safety of NRT [10, 11] and recommended removal of licence restrictions concerning people with stable cardiovascular disease and concurrent use while smoking [12] .
Temporary nicotine preloading is thus likely to be safe. The combined tailoring and preloading intervention, however, is an approach that has not been tried before. We undertook a pilot study to examine the acceptability and safety of gradually increasing nicotine dosing and the effects this has on smoking behaviour and enjoyment of smoking.
METHODS

Study design
A cohort of fifty smokers seeking treatment were provided with gradually increasing doses of nicotine patches (up to 84 mg, tailored to participant reactions) for four weeks prior to their target quit day (TQD), followed by a gradual reduction to standard dose (21 mg) over four weeks post-TQD.
Participants and setting
Participants were recruited in Mar del Plata, Argentina, in June 2017 via Facebook and a mention of the study during a radio interview. Interested participants called the study centre and were pre-screened for eligibility.
Participants were eligible if they were ≥ 18 years of age and were daily smokers seeking help to quit. Participants were excluded if they were pregnant, breastfeeding or planning to conceive in the next 3 months; had a previous serious adverse reaction to the nicotine patch; suffered from cardiovascular disease or another serious medical condition; or were enrolled in another interventional study.
Procedures
Participants attended 9 weekly sessions in total; four prior to the TQD, one on the TQD and four post-TQD. At the baseline session, participants gave written consent and eligibility was confirmed. Baseline measures were completed and participants set a TQD in four weeks' time (i.e. after 4 weeks on patches). All participants were given a 1-week supply of 21 mg/24 hr nicotine patches to use over the next week and instructed to smoke ad-libitum, with the dose increasing over further weeks as described below. Participants were told that they would be asked about any side effects at each weekly contact, and if they felt uncomfortable, the dose would be reduced. They were also instructed to reduce the dose or stop using patches themselves at any time if they experienced severe nausea, sickness or dizziness, or were otherwise concerned.
At each additional session prior to the TQD, the patch dose was increased by 21 mg/day, up to a maximum of 84 mg/day, provided participants reported no significant nausea or adverse effects or indicated they do not wish to increase the dose further.
From the TQD onwards, participants were provided with weekly behavioural support, and were offered a fastacting oral NRT product, (e.g. nicotine gum) alongside the patch. Participants remained on their high dose patch during the first week post-TQD, and then reduced by 21 mg/day each week until the end of the study period. NRT was provided free of charge.
Following the end of the intervention at 4 weeks post-TQD, participants were offered free standard stop-smoking medication and behavioural support for a further four weeks if they needed it. Only five participants took up this offer.
The study was approved by the Committee of Ethics and Research, Instituto Ave Pulmo and Joint Commission for Health Research, Buenos Aires State.
Intervention
We used 21 mg/24 hour nicotine patches manufactured by Novartis, and purchased from GlaxoSmithKline (GSK). Figure 1 shows the dosing schedule. All participants started at the standard dose of 21 mg/day. The dose was not increased (and could be decreased) if they reported they had felt 'very' or 'extremely' nauseous over the previous week; if other adverse effects were reported; or if the participant did not wish to increase the dose for any reason.
Participants began to reduce their dose by 21 mg/day each week one week post-TQD, until they reverted back to the standard dose (21 mg/day) at 4 weeks post-TQD.
Participants were advised to wear only one patch overnight and wear the additional patches during waking hours only.
Participants were advised to continue to smoke ad-libitum throughout the pre-quit period.
Measures
Demographics and smoking history data, including the Fagerström Test of Cigarette Dependence (FTCD) [13] were collected at baseline. At each pre-TQD visit, participants reported their cigarette consumption, gave a carbonmonoxide reading in expired breath (CO), and self-reported on any adverse effects and their patch use (days used per week; number of patches used/day; reasons for not using patches if applicable). They also rated their enjoyment of smoking: 'Have you found cigarettes more or less enjoyable since your last visit?' (1 = much less; 2 = slightly less; 3 = the same; 4 = slightly more; 5 = much more); nausea: 'Have you felt sick at all over the last week?' (1 = not at all to 5 = extremely); and helpfulness of the intervention: 'Did you find the nicotine patch helpful at all in reducing your smoking over the last week?' (1 = not at all to 5 = extremely).
Tobacco withdrawal symptoms and urges to smoke were measured via the Mood and Physical Symptoms Scale (MPSS) [14] , at baseline, on the TQD, and at 1 and 4 weeks post-TQD. The MPSS asks participants to rate common withdrawal symptoms including irritability, difficulty concentrating, depression, on a scale of 1 (not at all) to 5 (extremely), and the strength of urges to smoke from 1(no urges) to 6 (extremely strong), and frequency of urges to smoke from 1 (not at all) to 6 (all of the time). On the TQD, participants also rated, how easy the patches had been to use over the last 4 weeks; and how useful they were in preparing them for their quit day (both scales 1 = not at all to 5 = extremely).
At each post-TQD session, self-reported smoking status was established, and participants gave CO readings. Patch adherence, adverse effects and nausea ratings were collected, as well as information on additional stopsmoking medication use.
Study end-points
The primary end-point of the study was to determine the proportion of participants progressing through each stage of the dosing schedule.
Secondary end-points included: patch adherence and reasons for non-adherence; incidence of nausea and other adverse effects and their severity; effects of the intervention examined by: changes in cigarette consumption, CO and enjoyment of smoking, MPSS scores during the pre-quit period, changes in MPSS scores during the post-quit period, abstinence rates at the end of 4 weeks post-TQD (defined as 'not a single puff ' over the last two weeks, verified with a CO reading of <9 ppm at 4 weeks post-TQD) [15] ; ratings of the intervention (helpfulness, ease of use); and use of any other stop-smoking products. 
Sample size
For this descriptive pilot study, we opted for a cohort of 50 participants to assess the acceptability and feasibility parameters of the intervention quickly and economically.
Statistical analyses
Descriptive statistics were used to report on dosing progression, patch adherence, ratings of helpfulness, adverse events, and abstinence rates. Repeated measures ANOVA (or non-parametric alternative) was used to analyse changes over time in CO, cigarette consumption, nausea and enjoyment ratings, and ratings of tobacco withdrawal symptoms and urges to smoke.
RESULTS
Participants
Participant characteristics are shown in Table 1 . Eighty people responded to the radio and Facebook advertisements. No prospective participant refused participation after obtaining study details, but two were ineligible as they suffered from a serious medical condition.
Attendance, patch dose progression and adherence
Ninety-four percent of participants completed the trial (n = 47). Three participants dropped out of the study and this was unrelated to the increased patch dosing as one did not start the patch increase regimen, and the other two dropped out during the patch reduction period (one did not attend from 1 week post-TQD and the other did not attend the final session at 4 weeks post-TQD). Table 2 shows the number of participants progressing through each stage of the dosing schedule, and the adherence to each dose administered.
Adherence to the patches and dosing schedule was high. The only reason given for not using the assigned number of patches/day were adverse effects (see below); and the main reason given for not using patches every day was 'forgetting'.
Participants progressing to the maximum patch dose (n = 36, 72.0%) smoked more cigarettes per day at baseline (22.1 [8.8] vs 15.3 [4.9] , U = 135.5, P = 0.02) than those who did not progress (n = 13).
Nausea ratings and other adverse effects
There was a small but significant increase in nausea ratings from baseline to TQD (z = À3.5, P < 0.001) though the ratings remained low (see Table 3 ).
The number of adverse effects (AEs) increased as patch dose increased (see Table 4 ). The most common AEs were nausea, followed by vomiting. À4 to À1 = weeks pre-target quit day (TQD); 1-4 = weeks post-TQD.
b
Using the prescribed dose on at least 5 days/week. SD = standard deviation.
Two participants rated their AE's as 'severe', both at 63 mg dose. One reported headaches, nausea and feeling faint; the other experienced nausea and blurry vision.
Smoking behaviour and enjoyment of smoking
During the pre-quit period, the number of cigarettes smoked per day reduced significantly from 20/day at baseline to 6/day by the TQD (F (1,48) = 191.0; mean difference: 14.27, P < 0.001, 95%CI: 12.19-16.34). There was also a significant decrease in CO, from 19 ppm at baseline to 10 ppm by the TQD (F (1,48) = 71.6; mean difference: 9.86 P < 0.001, 95%CI: 7.52-12.20) (see Table 3 ).
There was a significant decrease in enjoyment from baseline to the TQD. The mean (SD) ratings were: 2.9 (0.6) and 1.8 (1.0) at TQD, F(1,41) = 29.6; mean difference: 1.10, P < 0.001, 95%CI: 0.69-1.50.
Urges to smoke
Both the frequency and strength of urges to smoke reduced significantly from baseline In participants who were abstinent in the first week post-TQD (n = 39), there was little evidence of change in composite urges to smoke: 2.3 (0.7) to 2.2 (0.8), P = 0.51). In participants who were abstinent at 4 weeks post-TQD (n = 41), composite ratings of urges to smoke also did not change significantly from TQD to 4 weeks post-TQD (2.3 [0.8] to 2.1 [0.7], P = 0.19).
Withdrawal symptoms
In participants who were abstinent in the first week post-TQD (n = 39), there was little evidence of change in composite MPSS scores from TQD to 1 week post-TQD (1.7 [0.6] to 1.9 [0.6], respectively; P = 0.14). In participants who were abstinent at 4 weeks post-TQD (n = 41), composite MPSS ratings did not change from TQD to 4 weeks post-TQD (1.69 [0.6] to 1.66 [0.5], P = 0.71).
Abstinence rates
Forty-one participants (82%) were abstinent at 4 weeks post-TQD and 37 (74%) were abstinent continuously (not a puff from the TQD, biochemically verified). Have you found cigarettes more or less enjoyable since your last visit? (1 = much less; 2 = slightly less; 3 = the same; 4 = slightly more; 5 = much more). NB for Enjoyment of Smoking: 1 = missing, and seven could not answer the question, as they had already quit smoking. SD = standard deviation; CO =carbon monoxide; TQD = target quit day. 
Ratings of the patch treatment
There was a significant increase in ratings of helpfulness of the patches in reducing smoking over the four weeks from baseline to the TQD (mean difference: À1.66, P < 0.001, 95%CI: -2.03--1.28). (see Table 3 ). At the TQD, the majority of participants (59%, n = 29) rated the patch pre-loading as 'very useful' in helping them prepare for their quit day. None of the participants said it was 'not at all' useful. Over half of the participants (59%, n = 29) reported that the patch pre-loading intervention was 'extremely easy' to do while 18 (37%) considered it to be 'very easy'.
Patches continued to be perceived as helpful during the post-quit period as well, with mean ratings of 3.9 (1.0), 3.6 (1.0), 3.7 (1.0) and 3.2 (1.1) at weeks 1-4 post-TQD, respectively.
Use of additional stop-smoking products
All participants took up the offer of additional oral NRT. Twenty-eight chose 4 mg gum and twenty-one chose 2 mg gum. Between 22 to 28 participants used nicotine gum for at least 5 days on a given week following the TQD alongside the patches, some in combination with nasal spray (n = 2) or both nasal spray and nicotine lozenge (4 mg) (n = 1) (see Table 5 ).
Fourteen participants consistently used additional NRT each week for at least 5 days/week. These regular users smoked significantly more cigarettes per day at baseline than non-regular users (26. 
DISCUSSION
In this first study of progressive nicotine pre-loading, the intervention was acceptable to smokers and associated with a marked reduction of enjoyment of smoking and smoke intake, and a high short-term abstinence rate. The intervention was rated as helpful and easy to adhere to. Two thirds of participants progressed to the highest nicotine dose. About a quarter of participants experienced nausea at higher patch doses, but this was mostly mild and well tolerated. Only two participants rated their side effects as 'severe', both at dosages of 63 mg (both reduced their dose back to 42 mg/day).
Regarding the feasibility and acceptability of the intervention, it was well received, and retention was unusually high, with only 6% of participants dropping out of treatment and none dropping out because of patch side effects. Providing treatment free of charge may have contributed to this, but other studies that provide free treatment normally experience much higher drop-out rates [6, 16] . The high adherence and positive acceptance of the intervention could have been in part at least related to the fact that the dose progression was guided by patient preferences and reactions, rather than prescribed by therapists on the basis of measures of dependence or pre-treatment nicotine intake. Smokers determine their nicotine intake while they smoke. The notion that the therapist rather than the patient should decide on nicotine dose for therapeutic purpose may well be counterproductive. Low drop-out could also be explained by the short time-frame of the study.
Rather surprisingly, 90% of participants progressed to three patches and two thirds progressed to four. In addition to wearing up to four full strength nicotine patches, over half of the participants further supplemented their treatment with additional NRT. The original NRT dosing was established some 40 years ago when providing nicotine to smokers was a new idea and there were concerns about treatment toxicity and especially its addictiveness [17] . These proved unsubstantiated. Non-smokers did not become dependent on NRT products and no adverse health effects associated with NRT use materialised [17] [18] [19] . Even among smokers, dependence on NRT and especially on patches proved to be rare [20] [21] [22] . Our results suggest that many smokers can tolerate much higher doses than those offered by current NRT products and that the evaluation of such dosing is warranted. It is possible that the early Table 5 Use of additional stop-smoking products post-target quit day (TQD).
NRT Product
Number of participants using product (>4 days/week) caution that is responsible for the very low NRT dosing is harming treatment efficacy. The fact that the progression to the highest dose was significantly linked to pre-treatment smoke intake suggests that the individualised approach successfully ensured that heavy smokers obtained the dose they can benefit from, while lighter smokers were able to remain at lower doses.
In terms of potential efficacy of the intervention, the validated abstinence rate (82%) was very high. The study centre operates a routine stop-smoking clinic, and clinic records (unpublished) show an overall quit rate of 45% at four weeks. The UK stop smoking services have a 4-week validated quit rate of 35% [23] . This finding is thus encouraging, but comparing abstinence rates across cohorts needs to be interpreted with caution.
It is remarkable that during the post-quit period, abstaining participants noticed no increase in the usual withdrawal symptoms, including urges to smoke. This could be due to both the effects of pre-loading and the fact that high nicotine dosing continued in the post-quit period.
The main hypothesis we were testing is that nicotine preloading reduces enjoyment of smoking and the number of cigarettes smoked. This could be based on two mechanisms. Firstly, with nicotine receptors occupied with nicotine from patches, smoking should provide less pharmacological reward. Secondly, if nicotine levels delivered by pre-loading are high enough, additional nicotine intake from cigarettes should cause nausea and so become aversive. We recorded a significant decline in enjoyment of smoking throughout the pre-loading period while cigarette consumption declined as well. Although expectations could have contributed to this, there was also a significant and progressive decline in smoke intake indexed by CO readings that traced closely the reported reduction in consumption as well as a reduction in enjoyment of smoking. In fact, participants reduced their smoke intake by over 50%. Unaided reduction in cigarette consumption is normally accompanied by compensatory smoking [24, 25] . Our findings suggest that the nicotine pre-loading made smoking genuinely less attractive.
As the intervention aims to generate the experience of non-rewarding or aversive cigarettes, we considered it important to encourage participants to smoke ad-lib. More frequent smoking provides more opportunities to weaken the association of smoking behaviour with central effects of nicotine. The new pre-loading trial mentioned in the introduction [9] also encouraged smoking ad-lib, and also found that the intervention reduced urges to smoke and enjoyment of smoking compared to no pre-loading, but the trial did not include placebo control and so expectation effects cannot be ruled out.
The study had several limitations. With no placebo control, the abstinence data are only indicative. Additionally, the reported reduction in enjoyment of smoking may have been influenced by expectations, although the reduction in smoke intake should be less vulnerable to such effects. With a sample size of 50, rare adverse reactions cannot be excluded. We also did not verify patch use objectively (e.g. by having participants return unused patches), and relied only on self-report.
The 'real-world' use of this approach could increase treatment costs. The cost of the patches at the full dosing schedule would be approximately $333 in Argentina and $263 (£200) in the UK. Questions arise as to what degree of improvement in treatment efficacy is needed for the intervention to be as cost-effective or more cost-effective than the current standard dosing; and whether with preloading, post-quit patch use could be shortened.
In summary, the intervention was feasible, accompanied by good adherence and an encouraging abstinence rate. Side effects were limited and generally well tolerated. Importantly, the intervention reduced the enjoyment of smoking, cigarette consumption and smoke intake during the pre-quit period. The intervention is promising enough to warrant a randomised trial.
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